<DOC>
	<DOCNO>NCT02517385</DOCNO>
	<brief_summary>Primary Objective : To assess safety Phosphatidylcholine paste 600 mg ( ESSENTIALE® paste ) oral 3 time day 12 week patient gastrointestinal symptom acute chronic liver disease . Secondary Objectives : To assess effectiveness symptomatic improvement patient gastrointestinal symptom acute chronic liver disease . To monitor compliance .</brief_summary>
	<brief_title>Essentiale® Paste Patients With Gastrointestinal Symptoms Acute Chronic Liver Diseases</brief_title>
	<detailed_description>The total study duration per patient 13 week consist 1-week pre-screening period 12-week treatment period .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion criterion : Males females ≥18 year age less 66 year old . Patients gastrointestinal symptom ( fatigue , abdominal pain/discomfort , early satiety , fullness discomfort meal , nausea/vomiting , belching/abdominal distension , least one rat `` Moderate Problem '' high severity screen visit ) acute chronic liver disease receive conventional treatment underlie pathology . Before enter study , patient advise stop alcohol intake must agree consume alcohol undergo alcohol withdrawal program , diet control , exercise program . The patient able willing undertake study require procedure ability take oral medication . Patients nonalcoholic fatty liver disease ( NAFLD ) diagnose ultrasound examination absence severe fibrosis per Investigator 's judgment . Diagnosis acute chronic viral hepatitis manifest combination follow symptom : jaundice ( acute viral hepatitis ) , darkcolored urine ( acute viral hepatitis ) , lightcolored stool ( acute viral hepatitis ) , pruritus , pruritic red hive , fever , nausea , vomit , anorexia , aversion smoking right upper abdominal discomfort , pain feeling pressure , abnormal alanine aminotransferase ( ALT ) ( approximately 1.5 x upper limit normal [ ULN ] ) . Patient give write informed consent . Fertile patient must agree use acceptable method contraception avoid pregnancy duration study : Total abstinence sexual intercourse ( minimum one complete menstrual cycle prior study drug administration ) . Vasectomized partner female subject . Hormonal contraceptive . Doublebarrier method ( condoms diaphragm vaginal cap plus spermicidal sponge , jelly , cream ) . Intrauterine Device ( IUD ) . Exclusion criterion : Patients &lt; 18 year age &gt; 66 year old . Female patient childbearing potential without negative pregnancy test . Breastfeeding woman . Hypersensitivity phosphatidylcholine substance product . Patient know human immunodeficiency virus ( HIV ) positive . Congenital lack α1 antitrypsin . Gastroesophageal Reflux Disease ( GERD ) . Autoimmune hepatitis . Fulminant hepatitis . Severe steatohepatitis : transaminase level beyond 5 time upper normal range . Previous liver biopsy demonstrate great equal 15 % steatosis . Evidence decompensated liver disease define follow : serum albumin &lt; 3.2 g/dL , total bilirubin &gt; 1.5 mg/dL , prothrombin time/international normalize ratio &gt; 1.3 time normal screening , history presence ascites encephalopathy , bleed esophageal varix . Diagnosis cancer . Parenteral nutrition . Advanced liver disease ( eg , ascites , bleed esophageal varix , hepatic encephalopathy , cancer hepatic metastasis ) . History serious chronic liver disease , include serious metabolic disease , document appropriate test ( ) . Evidence upper abdomen organic serious disease ( ulcer , etc. ) . Platelet count &lt; 130 000 cells/mm^3 . Serum creatinine level &gt; 1.5 time upper limit normal screening , creatinine clearance &lt; 60 cc/min , currently dialysis . History drug abuse within year prior Day 0 . Current recent use ( within 15 day screen ) hepatoprotector drug . Use warfarin , metronidazole , chronic use acetaminophen/paracetamol great three gram per day . Use oral steroid within 30 day prior screen . Use concomitant medication disturb liver function CYP3A4 inducer . Patients take drug able induce fatty liver 3 month within 1 year participation study ; ( ie , amiodarone , tamoxifen , methotrexate , tetracycline , glucocorticoid , usual dose estrogen hormone replacement therapy , valproate , St. John 's Wort , etc. ) . Patients take medication could affect treatment nonalcoholic steatohepatitis : insulin , insulin sensitizer ( ie , metformin , thiazolidinedione , high dose vitamin E , high dose ursodeoxycholic acid , pentoxifylline , Sadenosyl methionine , betaine , type statin , type fibrate , orlistat , etc. ) . History solid organ bone marrow transplantation . History current immunologically mediated disease ( eg , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hepatitis , autoimmune hemolytic anemia , severe psoriasis , rheumatoid arthritis , polyorganic pathology ) could affect inflammatory biomarkers . History current thyroid disease poorly control prescribed medication . History current significant renal , endocrine , cardiac , pulmonary disease . Other serious liver disease systemic pathology ( malignancy , central nervous system ) . Some example severe hypertension , morbid obesity ( body mass index &gt; 40 ) , severe mental illness , diabetes type 1 , poorly control diabetes type 2 . Other condition , Investigator 's opinion , make patient unsuitable enrollment ( coronary artery disease active gastrointestinal condition might interfere drug absorption ) . The patient currently participate clinical trial ( marketed product otherwise ) do within 30 day prior screen visit . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>